Suppr超能文献

suPAR 作为全身炎症或感染患者的生物标志物的效用:系统评价。

Usefulness of suPAR as a biological marker in patients with systemic inflammation or infection: a systematic review.

机构信息

Department of Intensive Care Medicine, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.

出版信息

Intensive Care Med. 2012 Sep;38(9):1418-28. doi: 10.1007/s00134-012-2613-1. Epub 2012 Jun 16.

Abstract

PURPOSE

Systemic levels of soluble urokinase-type plasminogen activator receptor (suPAR) positively correlate with the activation level of the immune system. We reviewed the usefulness of systemic levels of suPAR in the care of critically ill patients with sepsis, SIRS, and bacteremia, focusing on its diagnostic and prognostic value.

METHODS

A PubMed search on suPAR was conducted, including manual cross-referencing. The list of papers was narrowed to original studies of critically ill patients. Ten papers on original studies of critically ill patients were identified that report on suPAR in sepsis, SIRS, or bacteremia.

RESULTS

Systematic levels of suPAR have little diagnostic value in critically ill patients with sepsis, SIRS, or bacteremia. Systemic levels of suPAR, however, have superior prognostic power over other commonly used biological markers in these patients. Mortality prediction by other biological markers or severity-of-disease classification system scores improves when combining them with suPAR. Systemic levels of suPAR correlate positively with markers of organ dysfunction and severity-of-disease classification system scores. Finally, systemic levels of suPAR remain elevated for prolonged periods after admission and only tend to decline after several weeks. Notably, the type of assay used to measure suPAR as well as the age of the patients and underlying disease affect systemic levels of suPAR.

CONCLUSIONS

The diagnostic value of suPAR is low in patients with sepsis. Systemic levels of suPAR have prognostic value, and may add to prognostication of patients with sepsis or SIRS complementing severity-of-disease classification systems and other biological markers.

摘要

目的

可溶性尿激酶型纤溶酶原激活物受体(suPAR)的系统水平与免疫系统的激活水平呈正相关。我们回顾了全身性 suPAR 水平在脓毒症、全身炎症反应综合征和菌血症危重症患者治疗中的作用,重点关注其诊断和预后价值。

方法

对 suPAR 进行了 PubMed 检索,包括手动交叉引用。将论文列表缩小到危重症患者的原始研究。确定了 10 篇关于脓毒症、全身炎症反应综合征或菌血症危重症患者 suPAR 的原始研究论文。

结果

系统性 suPAR 水平在脓毒症、全身炎症反应综合征或菌血症的危重症患者中诊断价值有限。然而,全身性 suPAR 水平在这些患者中比其他常用的生物学标志物具有更好的预后价值。当将其他生物学标志物或疾病严重程度分类系统评分与 suPAR 结合使用时,对死亡率的预测会得到改善。全身性 suPAR 水平与器官功能障碍标志物和疾病严重程度分类系统评分呈正相关。最后,全身性 suPAR 水平在入院后持续升高很长一段时间,仅在数周后才开始下降。值得注意的是,用于测量 suPAR 的检测方法类型、患者年龄和基础疾病会影响全身性 suPAR 水平。

结论

suPAR 的诊断价值在脓毒症患者中较低。全身性 suPAR 水平具有预后价值,可能会增加脓毒症或全身炎症反应综合征患者的预后,补充疾病严重程度分类系统和其他生物学标志物的预后。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4cce/3423568/fc77aa754c4f/134_2012_2613_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验